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Apoptosis and autophagy are crucial mechanisms regulating cell death, and the relationship between
apoptosis and autophagy in the liver has yet to be thoroughly explored. TIGAR (TP53-induced glycolysis
and apoptosis regulator), which is a p53-inducible gene, functions in the suppression of ROS (reactive
oxygen species) and protects U2OS cells from undergoing cell death. In this study, silencing TIGAR by
RNAi (RNA interference) in HepG2 cells down-regulated both TIGAR mRNA (75%) and protein levels
(80%) and led to the inhibition of cell growth (P < 0.01) by apoptosis (P < 0.001) and autophagy. We
demonstrated that TIGAR can increase ROS levels in HepG2 cells. The down-regulation of TIGAR led to
the induction of LC-3 II (speciﬁc autophagic marker), the formation of the autophagosome, and increased
Beclin-1 expression. 3-MA (3-Methyladenine), an inhibitor of autophagic sequestration blocker, inhibited
TIGAR siRNA-enhanced autophagy, as indicated by the decrease in LC-3 II levels. Consequently, these data
provide the ﬁrst evidence that targeted silencing of TIGAR induces apoptotic and autophagic cell death in
HepG2 cells, and our data raise hope for the future successful application of TIGAR siRNA in patients with
hepatocellular carcinoma (HCC).
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Currently, HCC ranks among the ﬁve most important causes of
cancer-related mortality worldwide [1]. The dysregulation of the
balance between proliferation and cell death represents a protu-
morigenic principle in human hepatocarcinogenesis and is mainly
due to the overactivation of antiapoptotic and antiautophagic sig-
nals. Apoptosis (programmed cell death type I) and autophagic celldeath (programmed cell death type II) are crucial physiological
mechanisms that control the development, homeostasis, and elim-
ination of unwanted and malignant cells [2,3]. Overactivation of
antiapoptotic signals contributes to tumorigenesis and chemother-
apy resistance in HCC cells [4]. Recent data demonstrated that
autophagy is involved in the major ﬁelds of hepatology. In HCC,
the autophagy levels are reduced, and autophagy plays an anti-
tumor role and has a beneﬁcial effect in patients with HCC [5,6].
Collectively, these data indicate that the status of apoptosis and
autophagy is a key factor that determines therapeutic response
to HCC therapies. Therefore, therapeutic strategies to inhibit selec-
tively antiapoptotic or antiautophagic signals in HCC cells have the
potential to provide powerful tools to treat HCC. If siRNA becomes
therapeutically practical, antiapoptotic and antiautophagic pro-
teins would be potential therapeutic targets [7].
It has been determined that TIGAR is a p53-induced apoptosis
and autophagy regulator, and it plays an essential role in apoptosis
induced by both nuclear and cytoplasmic p53 [8,9]. Previous stud-
ies have demonstrated that TIGAR expression correlates with the
ability to protect cells from ROS-associated apoptosis; conse-
quently, knockdown of endogenous TIGAR expression sensitizes
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therefore modulate the apoptotic response to p53, allowing cellu-
lar survival in the face of mild or transient stress signals that may
be reversed or repaired. Previous studies have also demonstrated
that the modulation of intracellular ROS levels by TIGAR can func-
tion in limiting autophagy in U2OS cells [8].
We hypothesized that the expression of TIGAR can affect the
balance between cell growth and cell death and that TIGAR modu-
lation inﬂuences apoptosis and autophagy in HepG2 cells. To inves-
tigate the role of TIGAR in apoptosis and autophagy in HepG2 cells,
we transfected cells with siTIGAR (siRNA targeting TIGAR) to regu-
late speciﬁcally the expression of TIGAR. We determined that the
silencing of TIGAR regulated ROS levels and increased speciﬁc
autophagic protein expression that resulted in the induction of
apoptosis and autophagy in HepG2 cells. These data demonstrate
a novel mechanism for growth inhibition induced by TIGAR knock-
down in HepG2 cells. Better understanding of the mechanisms in-
volved in siTIGAR-induced cell death may hold the promise of
better management of HCC in patients.2. Materials and methods
2.1. Cell lines and reagents
The HepG2 cell line was grown in Dulbeco’s Modiﬁed Eagle’s
Medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10%
fetal calf serum at 37 C in a 5% CO2. The cells were treated with
3-MA (Sigma–Aldrich, St. Louis, MO, USA) at a ﬁnal concentration
of 10 mM for 24 h before transfection. For the HBSS treatment,
the cells were nutrient starved for 2 h, and these cells were used
as a positive control.
2.2. Transfections with siRNAs and RT-PCR analysis
Exponentially growing, untreated HepG2 cells were plated at
2  105/well in 2 ml of medium for 24 h before transfection. The
plated cells were transfected with either the control siRNA, the
double-stranded siRNA targeting the TIGAR mRNA, or the transfec-
tion reagent alone. For the siRNA-mediated down-regulation of TI-
GAR, the following 4 siRNAs oligonucleotides were designed and
employed (Genepharm Co., Shanghai, China): siRNA-1 (siTIGAR-
80), 50-GAU GAA CCU CUU UCA GAA AdTdT-30; siRNA-2 (siTIGAR-
225), 50-GCA AAG AUA UGA CGG UAA AdTdT-30; siRNA-3
(siTIGAR-496), 50-GGC AGA GAU AUU UCC UUU AdTdT-30; siRNA-
4 (siTIGAR-772), 50-CCU ACA GGA UCA UCU AAA UdTdT-30. The
non-silencing control siRNA (siCON) duplexes were synthesized
using scrambled sequences. siRNA transfection was performed
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) accord-
ing to the manufacturer0s instructions. Brieﬂy, on the day the cells
were transfected, the medium was removed and replaced with
1 ml of fresh medium. One microgram of siRNA was mixed with
the transfection reagent and then added to each well. For the RT-
PCR analysis, cells were collected and total RNA was isolated using
Trizol reagent (Invitrogen, Carlsbad, CA, USA), and then cDNA was
obtained using PCR. The real-time PCR ampliﬁcation was per-
formed using QuantiTect SYBR green (Qiagen, CA, USA) following
the manufacturer’s instructions. The TIGAR (50-AGG GAA GAG
TGC CCT GTG TT-30) and GAPDH-speciﬁc primers were used in
the real-time PCR reactions. The CT (threshold cycle) value of TIGAR
ampliﬁcation was normalized to that of the GAPDH control.
2.3. Western blot analysis
After treatment with siCON, siTIGAR or HBSS, the cells
were harvested. Proteins were separated using 12% (w/v)SDS–polyacrylamide gel electrophoresis (PAGE) gels and trans-
ferred to PVDF membranes. After blocking in PBS/Tween (0.01%)
with 5% nonfat milk, the membrane was incubated with the pri-
mary antibodies at 4 C overnight. The following antibodies were
used: TIGAR (1:1,250; Abcam Inc., Cambridge, UK); b-actin
(1:5000; Sigma–Aldrich, St. Louis, MO, USA); LC3 (1:500; Abcam
Inc., Cambridge, UK); Beclin-1(1:500; Abcam Inc., Cambridge,
UK). The membranes were then incubated with secondary anti-
body conjugated to horseradish peroxidase, the bands were visual-
ized using enhanced chemiluminescence (Pierce, IL, USA), and the
blots were exposed to ﬁlm (Kodak, USA). The ﬁlms were scanned
using a CanonScan scanner for data quantiﬁcation, and the ac-
quired images were then analyzed on a computer using the public
domain NIH image program (http://rsb.info.nih.gov/nih-image/).
2.4. MTT assay
Cell viability was assessed using an MTT (3-(4,5-Dimethylthia-
zol-2-yl)-2,5-Diphenyltetrazolium Bromide) reduction assay as de-
scribed previously [10]. Brieﬂy, HepG2 cells were incubated with
10% MTT (Sigma–Aldrich) solution in DMEM medium for 30 min
at 37 C. The extent of MTT conversion to formazan by mitochon-
drial dehydrogenase, which is indicative of cell viability, was deter-
mined by measuring the absorbance at a wavelength of 490 nm
using a microplate reader (Bio-Rad Laboratories, Hercules, CA,
USA).
2.5. In situ TUNEL assay
After siCON or siTIGAR treatment in HepG2 cells, apoptosis was
assayed using a commercially available terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) assay kit (Roche, Man-
heim, Germany). The total number of TUNEL positive cells divided
by the total number of cells (DAPI staining of nuclei) was used to
indicate the percentage of apoptosis. At least ten images were
acquired from each immunostained treatment group using an
Olympus microscope.
2.6. MDC staining
The autoﬂuorescent agent MDC (monodansyl cadaverine) (Sig-
ma, St. Louis, MO, USA) was recently introduced as a speciﬁc auto-
phagolysosome marker to analyze autophagic process [11]. HepG2
cells were plated into 24-well plates at 0.2  106 cells/well 24 h
before siRNA treatment. The cells were transfected with siTIGAR,
control siRNA, or left untreated for 72 h. The control and treated
cells were harvested using trypsin–EDTA and washed in 1 ml of
phosphate-buffered saline (PBS). Autophagic vacuoles were then
labeled with MDC by incubating the cells with 50 lM MDC in
DMEM at 37 C for 10 min. After incubation, the cells were washed
twice with PBS and immediately analyzed by FACS analysis.
2.7. Transmission electron microscopy
HepG2 cells were grown on six-well plates and transfected with
siTIGAR or control siRNA, ﬁxed for 2 h with 2.5% glutaraldehyde in
0.1 M cacodylate buffer (pH 7.4), post-ﬁxed in 1% OsO4 in the same
buffer, and then subjected to electron microscope analysis as
described previously. Representative areas were chosen for ultra-
thin sectioning and viewed using a Philip electron microscope
(Eindhoven, Netherlands).
2.8. Statistical analyses
All experiments were performed in triplicate, and the data were
analyzed using one-way analysis of variance (ANOVA) followed by
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as the mean ± S.D., and the criterion for statistical signiﬁcance was
P < 0.05.3. Results
3.1. TIGAR-speciﬁc siRNA down-regulates TIGAR expression in HepG2
cells
RNAi was performed by transfecting siRNA to speciﬁcally
knockdown TIGAR expression in HepG2 cells. We ﬁrst investigated
the transfection efﬁciency of siRNA by using FAM-labeled negative
control siRNA and found that the efﬁciency was more than 85%
(12 h transfection) (data not shown). Next, we evaluated a time-
course of GAPDH siRNA (siGAPDH)-induced changes in GAPDH
mRNA and protein level in HepG2 cells at 12, 24, 48, 72 h post-
transfection (Fig. 1A). We observed that siGAPDH-induced the
down-regulation of GAPDH RNA and protein starting at 24 h
(RNA) or 48 h (protein) and reaching maximum down-regulation
at 48 h (RNA) (Fig. 1A) or 72 h (protein) (data not shown) post-
transfection. Therefore, for siTIGAR study we used the 48 h post-
transfection time point for RNA studies and 72 h post-transfection
for protein studies.
TIGAR expression was then measured using quantitative real-
time PCR. We treated HepG2 cells with four different siRNAs tar-
geting TIGAR (siRNA 1, 2, 3 and 4). Based on the real-time PCR data
from the 48 h treatment samples, these siRNAs decreased TIGAR
RNA by approximately 50%, 30%, 20%, and 75%, respectively, rela-
tive to the control cells (Fig. 1B). We next investigated the inhibi-
tion of TIGAR protein by performing a western blot on samples
from 72 h post-transfection. As shown in Fig. 1C, TIGAR and b-actin
expression levels were determined and, siTIGAR down-regulated
the TIGAR protein. Similar to the real-time PCR result (Fig. 1B),
the western blot (Fig. 1D) also demonstrated that siRNA 4 (siTIGAR
772) had the greatest interference efﬁciency (nearly 80%) out of theFig. 1. RNAi of GAPDH and TIGAR. (A) HepG2 cells were transfected with siGAPDH for 12
(B) HepG2 cells were treated with either siCON or siTIGAR (1, 2, 3, and 4) for 48 h. The T
level. (C) After 72 h of siCON and siTIGAR treatments, the protein extracts were subjecte
were normalized as a ratio to actin after densitometrical quantiﬁcation and presented a
from three independent experiments. ⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.0001 compared withfour siRNAs. Therefore, from this point we only used siTIGAR4 for
the remaining experiments, and henceforth dubbed ‘‘siTIGAR’’.3.2. HepG2 cells undergo cell death and apoptosis upon TIGAR knock
down
We ﬁrst investigated whether the inhibition of TIGAR expres-
sion by siRNA alone results in enhanced growth inhibition and cell
death in HepG2 cells. Treating HepG2 cells using siTIGAR caused
cell death, as detected using an MTT assay (Fig. 2A). A time-depen-
dent decrease in HepG2 cell viability was tightly associated with
the down-regulation of TIGAR protein following siTIGAR treat-
ment, but this was not observed using the same dose of the nega-
tive control (data not shown). After TIGAR was silenced by RNAi for
72 h, cell viability decreased dramatically relative to the untreated
control and the non-silencing siRNA control cells (Fig. 2A).
Knockdown of endogenous TIGAR protein has been shown to
induce apoptosis in U2OS cells [9], and the expression of TIGAR
may modulate the apoptotic response to p53. To understand the
cell death mechanism in HepG2 cells, which occurred in TIGAR-
down-regulated cells, we next investigated whether knockdown
of TIGAR expression by siRNA alone can activate apoptotic signal-
ing in HepG2 cells. Therefore, HepG2 cells were transfected with
siRNA targeting TIGAR or non-silencing control siRNA. Twenty-four
hours after transfection, the cells were using a TUNEL apoptosis as-
say. TUNEL staining indicated that the apoptosis rate of the trans-
fected HepG2 cells was approximately 35%, which was triggered by
the down-regulation of TIGAR expression by RNAi. Previous studies
have shown that TIGAR can inhibit apoptosis by limiting ROS levels
and was not effective at regulating non-ROS-dependent apoptosis
[9]. Therefore, we detected the intracellular ROS levels in HepG2
cells after TIGAR was silenced and found that TIGAR had the ability
to decrease ROS levels (Fig. 2C). Similar to the observations in the
previous study, our data indicated that TIGAR can control ROS
accumulation and inhibit apoptosis, which is related to ROS level., 24, 48 and 72 h. GAPDH and b-actin mRNA levels were detected by real-time PCR.
IGAR mRNA level was quantiﬁed by real-time PCR and normalized to GAPDH mRNA
d to western blot and b-actin was used as a loading control. (D) Levels of TIGAR (C)
s fold change relative to control. Results are expressed as the mean ± SD of samples
untreated group.
Fig. 2. siTIGAR induced cell death and apoptosis. (A) HepG2 cells were transfected with either siCON or siTIGAR for 72 h. Cell viability of HepG2 cells were assessed by MTT
assay. Results are expressed as average ± SD of triplicate sample. (B) Using TUNEL assay to examine the siTIGAR-induced apoptosis at 24 h posttreatment. Photographs have a
magniﬁcation 20. (C) Apoptosis is expressed as percentage of TUNEL positive cells (green dots) over the total amount of cells (nuclei staining by DAPI, blue dots). For
quantiﬁcation, a minimum of 10 photos were analyzed. (D) ROS levels in HepG2 cells transfected with either siCON or siTIGAR for 24 h. ROS levels were measured by FACS
after transfection. The results are expressed as the mean DCF ﬂuorescence (±SD), from three independent experiments. ⁄⁄P < 0.01, ⁄⁄⁄P < 0.0001 compared with untreated
group. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
L. Ye et al. / Biochemical and Biophysical Research Communications 437 (2013) 300–306 3033.3. siTIGAR induces autophagic cell death
In mammalian cells, some data have suggested that apoptosis
and autophagy could participate in cell death, and the induction
of autophagy has been veriﬁed to enhance the apoptotic response
[12]. In fact, the connection between apoptosis and autophagy is a
developing area of research. One previous study demonstrated that
tetrandrine induced the production of ROS and autophgay, and the
treatment with ROS scavengers signiﬁcantly abrogated tetran-
drine-induced autophagy [13]. Recently, TIGAR has been shownto indirectly modulate ROS and function to inhibit autophagy
[9,14]. Because the TIGAR protein has been shown to protect cells
from undergoing apoptosis (Fig. 2B and C) by modulating ROS lev-
els (Fig. 2D), and ROS can regulate autophgay, we next investigated
the effect of siTIGAR on the induction of autophagy by performing
MDC staining. A previous study showed that MDC accumulates in
mature AVs (autophagic vacuoles), such as autophagolysosomes,
andMDC staining can be used to detect autophagic vacuoles. When
cells were analyzed by FACS, the 72-h siTIGAR-treated HepG2 cells
resulted in a signiﬁcant increase in the number of MDC labeled
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This result indicates that there is an induction of AV formation
by siTIGAR transfection.
Previous work showed that during the autophagy process,
microtubule-associated protein 1 light chain 3 (LC3) is converted
to LC3-I and conjugated to phosphatidylethanolamine to form
LC3-II, which is a hallmark of autophagy and located on the auto-
phagosomal membrane [15]. The expression of autophagy-speciﬁc
LC3-II was detected by western blot analysis. Both siTIGAR trans-
fection and HBSS treatment enhanced LC3-II levels in HepG2 cells
(Fig. 3B). To test if increased LC3-II levels were a result of increased
autophagosome formation, we further analyzed the induction of
autophagy and the ultrastructure of HepG2 cells by transmission
electron microscopy (Fig. 3C). As shown in Fig. 3C, siTIGAR cells
contained multiple cytoplasmic autophagic vacuoles (arrows in
Fig. 3d). We also observed abundant vacuolar elements after HBSS
treatment, which were most likely to be of autophagic origin (ar-
rows in Fig. 3f).
Collectively, our data clearly demonstrate that siTIGAR
treatment, but not siCON treatment (Fig. 3a and b), induced theFig. 3. siTIGAR induced autophagy in HepG2 cells. (A) HepG2 cells treated with siCON o
graph represents the percentage of MDC-positive cells. (B) LC 3-II expression was detec
Electron micrographs showed the ultrastructure of HepG2 cells treated with siCON (a and
vacuoles (indicated by arrows) were observed in the siTIGAR-treated and HBSS-treatedformation of double-membraned autophagic vesicles containing
cellular organelles with merging autophagic vesicles with lyso-
somes and lysed cellular content in the autophagosomes, indicat-
ing activity of lysosomal function and degradation.
3.4. Inhibition of TIGAR induces expression of Beclin-1 autophagy
promoting protein
To evaluate the contribution of an autophagic mechanism to
siTIGAR-induced cell death, the effects of the autophagy inhibitor
3-MA on siTIGAR-induced alterations in LC3-II proteins was de-
tected by western blot assay (Fig. 4A). Quantiﬁcation data
(Fig. 4B) indicated that pretreating with 3-MA signiﬁcantly inhib-
ited siTIGAR- and HBSS-induced autophagy. Recent developments
indicate that Beclin-1 is one of the most important mediators in
the formation of the autophagosome because it is involved in the
initial step of autophagosome formation [16].
To address whether Beclin-1 is involved in siTIGAR-induced
autophagy, the effect of siTIGAR on the expression of Beclin-1
was checked by western blot analysis. We determined thatr siTIGAR for 72 h. The cells were then stained with MDC for detection by FACS. Bar
ted after 72 h transfection or 2 h nutrient starvation by Western blot analysis. (C)
b) or siTIGAR (c and d) for 72 h or exposed to HBSS (e and f). Numerous autophagic
cells. ⁄P < 0.05 compared with untreated group.
Fig. 4. TIGAR expression modulates autophagy. (A) HepG2 cells were pretreated with 3-MA before siRNA transfection or nutrient starvation and were collected after 72 h
transfection. Protein extracts were subjected to western blot and b-actin was used as a loading control. Results are representative of three independent experiments. (B) The
ﬁlms were scanned and the acquired images were analyzed using the public domain NIH image program for data quantiﬁcation. Levels of LC3-II were normalized as a ratio to
b-actin after densimetrical quantiﬁcation and shown as percentage of control group. (C) HepG2 cells were treated with siRNA for 72 h or nutrient starvation for 2 h. Protein
extracts were subjected to western blot and b-actin was used as a loading control. (D) Densities of protein bands were analyzed with the public domain NIH image program.
Levels of Beclin-1 were normalized as a ratio to b-actin after densimetrical quantiﬁcation and shown as percentage of untreated group. ⁄P < 0.05, ⁄⁄P < 0.01compared with
untreated group, #P < 0.05.
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Quantiﬁcation data (Fig. 4D) showed that siTIGAR dramatically in-
creased Beclin-1 expression relative to siCON treatment. HepG2
cells exposed to HBSS also displayed upregulated Beclin-1
expression.
4. Discussion
Although the relationship between apoptosis and autophagy is
still a debated topic, and the functional relationship between apop-
tosis and autophagy within the carcinogenesis process is very com-
plex, there is mounting evidence that the combined inactivation of
apoptosis and autophagy contributes to tumorigenesis [17,18].
Previous studies have indicated that in HCC, antiapoptotic stimuli
inhibit apoptosis induced by various stress-inducing conditions
such as p53 activation and nutrient starvation [4,19]. Furthermore,
the heterozygous disruption of the B autophagy gene has been
shown to promote tumorigenesis and accelerate the development
of hepatitis B virus-induced premalignant, which results in in-
creased cellular proliferation and reduced autophagy in vivo.
Accumulating evidence indicates that autophagy plays dual
roles in cell death [20]. Some results suggest that autophagy is
harmful [21]; however, there are some reports that autophagy is
protective [22]. One recent study determined that the expression
of autophagic genes was extremely low in HCC cells, especially in
highly malignant HCC cells relative to low-grade malignant cells.
These data indicate that the malignant potential or differentiation
of HCC is only closely correlated with Beclin-1 expression in a Bcl-
xL-positive background [18].
One study showed that TIGAR has the ability to limit the level of
fructose-2, 6-bisphosphatase and via the induction of the pentosephosphate pathway TIGAR has an anti-apoptotic effect in U2OS
cells [9]. TIGAR also has been shown to translocate to the mito-
chondria and to interact with hexokinase 2, resulting in the regu-
lation of mitochondrial membrane potential and a reduction in
ROS levels [23]. However, recent studies have also highlighted
the important contribution of TIGAR to autophagy and determined
that the autophagy inhibitory function of TIGAR was tightly corre-
lated with the suppression of ROS. These ﬁndings indicate that TI-
GAR is very important for anti-programmed cell death.
The present study provides the ﬁrst evidence that the targeted
silencing of TIGAR expression results in enhanced apoptosis and
autophagy levels in HCC cells. Our ﬁndings support the hypothesis
that TIGAR plays an important role in protecting HepG2 cells from
cell death. Furthermore, our data demonstrate that ROS levels play
a critical role in siTIGAR-induced apoptosis and that Beclin-1
expression is responsible for autophagic cell death in HepG2 cells
(Fig. 4C and D). The reported structure of TIGAR [24] will further
help us to explore the mechanisms of siTIGAR-induced cell death.
In this paper, we used a chemically modiﬁed siRNA, which is
thought to be more stable and effective than a non-modiﬁed siRNA.
The introduction of siRNA targeting TIGAR into HepG2 resulted in
efﬁcient and speciﬁc inhibition of endogenous TIGAR expression,
as demonstrated by real-time PCR and western blotting. These re-
sults suggest that the prepared siRNA that targeted the TIGAR gene
is capable of inducing marked inhibitions of TIGAR RNA transcrip-
tion and signiﬁcant enhancement of apoptosis and autophagy in
HCC cell lines. Taken together, we demonstrated that the speciﬁc
down-regulation of TIGAR by RNAi is a promising approach to pro-
mote HCC cell apoptosis and autophagy and that this method has
potential to be a molecularly targeted therapy, thereby shedding
light on a potential new strategy in gene silencing therapy in HCC.
306 L. Ye et al. / Biochemical and Biophysical Research Communications 437 (2013) 300–306Acknowledgments
This work was supported by the National Key Program for Basic
Research of China (2010CB529902), the Science and Technology
Commission of Shanghai (13JC1406202) to Guanxiang Qian; the
National Natural Science Foundation of China (81172323,
81001008) to Shengfang Ge, and the research grants of National
Institutes of Health (R01 NS 41858-01, R01 NS 061642-01) to Jialin
C. Zheng.
References
[1] J.M. Llovet, A. Burroughs, J. Bruix, Hepatocellular carcinoma, Lancet 362 (2003)
1907–1917.
[2] C.W. Wang, D.J. Klionsky, The molecular mechanism of autophagy, Mol. Med. 9
(2003) 65–76.
[3] R.A. Gonzalez-Polo, P. Boya, A.L. Pauleau, A. Jalil, N. Larochette, S. Souquere, E.L.
Eskelinen, G. Pierron, P. Saftig, G. Kroemer, The apoptosis/autophagy paradox:
autophagic vacuolization before apoptotic death, J. Cell Sci. 118 (2005) 3091–
3102.
[4] T. Takehara, X. Liu, J. Fujimoto, S.L. Friedman, H. Takahashi, Expression and role
of Bcl-xL in human hepatocellular carcinomas, Hepatology 34 (2001) 55–61.
[5] P.E. Rautou, A. Mansouri, D. Lebrec, F. Durand, D. Valla, R. Moreau, Autophagy
in liver diseases, J. Hepatol. 53 (2010) 1123–1134.
[6] X. Qu, J. Yu, G. Bhagat, N. Furuya, H. Hibshoosh, A. Troxel, J. Rosen, E.L.
Eskelinen, N. Mizushima, Y. Ohsumi, G. Cattoretti, B. Levine, Promotion of
tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene, J.
Clin. Invest. 112 (2003) 1809–1820.
[7] K.C. Chang, J. Unsinger, C.G. Davis, S.J. Schwulst, J.T. Muenzer, A. Strasser, R.S.
Hotchkiss, Multiple triggers of cell death in sepsis: death receptor and
mitochondrial-mediated apoptosis, FASEB J. 21 (2007) 708–719.
[8] K. Bensaad, E.C. Cheung, K.H. Vousden, Modulation of intracellular ROS levels
by TIGAR controls autophagy, EMBO J. 28 (2009) 3015–3026.
[9] K. Bensaad, A. Tsuruta, M.A. Selak, M.N. Vidal, K. Nakano, R. Bartrons, E.
Gottlieb, K.H. Vousden, TIGAR, a p53-inducible regulator of glycolysis and
apoptosis, Cell 126 (2006) 107–120.
[10] M.V. Berridge, A.S. Tan, Characterization of the cellular reduction of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular
localization, substrate dependence, and involvement of mitochondrial electron
transport in MTT reduction, Arch. Biochem. Biophys. 303 (1993) 474–482.[11] D.B. Munafo, M.I. Colombo, A novel assay to study autophagy: regulation of
autophagosome vacuole size by amino acid deprivation, J. Cell Sci. 114 (2001)
3619–3629.
[12] D. Crighton, S. Wilkinson, J. O’Prey, N. Syed, P. Smith, P.R. Harrison, M. Gasco, O.
Garrone, T. Crook, K.M. Ryan, DRAM, a p53-induced modulator of autophagy, is
critical for apoptosis, Cell 126 (2006) 121–134.
[13] K. Gong, C. Chen, Y. Zhan, Y. Chen, Z. Huang, W. Li, Autophagy-related gene 7
(ATG7) and reactive oxygen species/extracellular signal-regulated kinase
regulate tetrandrine-induced autophagy in human hepatocellular carcinoma,
J Biol Chem 287 (2012) 35576–35588.
[14] B. Levine, J. Yuan, Autophagy in cell death: an innocent convict?, J Clin. Invest.
115 (2005) 2679–2688.
[15] Y. Kabeya, N. Mizushima, T. Ueno, A. Yamamoto, T. Kirisako, T. Noda, E.
Kominami, Y. Ohsumi, T. Yoshimori, LC3, a mammalian homologue of yeast
Apg8p, is localized in autophagosome membranes after processing, EMBO J. 19
(2000) 5720–5728.
[16] S. Pattingre, L. Espert, M. Biard-Piechaczyk, P. Codogno, Regulation of
macroautophagy by mTOR and Beclin 1 complexes, Biochimie 90 (2008)
313–323.
[17] A. Kotsafti, F. Farinati, R. Cardin, U. Cillo, D. Nitti, M. Bortolami, Autophagy and
apoptosis-related genes in chronic liver disease and hepatocellular carcinoma,
BMC Gastroenterol. 12 (2012) 118.
[18] Z.B. Ding, Y.H. Shi, J. Zhou, S.J. Qiu, Y. Xu, Z. Dai, G.M. Shi, X.Y. Wang, A.W. Ke,
B. Wu, J. Fan, Association of autophagy defect with a malignant phenotype
and poor prognosis of hepatocellular carcinoma, Cancer Res. 68 (2008)
9167–9175.
[19] T. Nishikawa, T. Nakajima, M. Moriguchi, M. Jo, S. Sekoguchi, M. Ishii, H.
Takashima, T. Katagishi, H. Kimura, M. Minami, Y. Itoh, K. Kagawa, T. Okanoue,
A green tea polyphenol, epigalocatechin-3-gallate, induces apoptosis of human
hepatocellular carcinoma, possibly through inhibition of Bcl-2 family proteins,
J. Hepatol. 44 (2006) 1074–1082.
[20] R.A. Nixon, Autophagy in neurodegenerative disease: friend, foe or turncoat?,
Trends Neurosci 29 (2006) 528–535.
[21] Y. Liu, M. Schiff, K. Czymmek, Z. Talloczy, B. Levine, S.P. Dinesh-Kumar,
Autophagy regulates programmed cell death during the plant innate immune
response, Cell 121 (2005) 567–577.
[22] N. Mizushima, B. Levine, A.M. Cuervo, D.J. Klionsky, Autophagy ﬁghts disease
through cellular self-digestion, Nature 451 (2008) 1069–1075.
[23] E.C. Cheung, R.L. Ludwig, K.H. Vousden, Mitochondrial localization of TIGAR
under hypoxia stimulates HK2 and lowers ROS and cell death, Proc. Natl. Acad.
Sci. USA 109 (2012) 20491–20496.
[24] H. Li, G. Jogl, Structural and biochemical studies of TIGAR (TP53-induced
glycolysis and apoptosis regulator), J. Biol. Chem. 284 (2009) 1748–1754.
